The Company's operating leases consist of facility and office equipment leases. Operating lease expenses was $0.3 million for each of the three months ended April 4, 2026 and March 29, 2025. Cash paid for operating leases totaled $0.3 million for both the three months ended April 4, 2026 and March 29, 2025. As of April 4, 2026, the weighted average discount rate used in calculating the present value of lease payments was 5.8%. As of April 4, 2026, the weighted average remaining lease term for the operating leases was 1.1 years.

The following represents maturities of operating lease liabilities as of April 4, 2026 (in thousands):


Fiscal Year	Operating Lease Payments
Remainder of 2026 (nine months)	$	421
2027		50
2028		46
2029		10
Total lease payments		527
Less: Imputed interest		(16	)
Total lease liabilities		511
Non-current portion of lease liabilities		(87	)
Current portion of lease liabilities	$	424

The Company’s purchase commitments consist primarily of non-cancellable purchase commitments with vendors to manufacture certain components and ophthalmic instrumentation. As of April 4, 2026, the Company’s future minimum payments through fiscal year 2028 for its purchase commitments were approximately $27.4 million, with $27.3 million committed for the next 12 months.

The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties (generally the Company’s business partners or customers) in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s products. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments that we could be required to make under these agreements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal.

The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of a culpable nature. These agreements also require the Company to advance their expenses incurred as a result of any proceeding against them as to which they could be indemnified and to make a good faith determination whether or not it is practicable for the Company to obtain directors and officers insurance. The Company currently has directors and officers liability insurance.

From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of these ordinary course matters will not have a material adverse effect on the Company’s condensed consolidated operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.